Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Vemurafenib in Melanoma with Brain Metastases
NCT01781026Phase 2Completed
- Sponsor
- Yale University
- Start
- Apr 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in melanoma, sponsored by Yale University. Primary endpoint: Activity of Vemurafenib in Untreated Brain Metastases at 1 year. Started Apr 2013; status: completed.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01781026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01781026.